Acrivon Therapeutics, Inc. Common Stock
NASDAQ: ACRV0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Peter Blume-Jensen
- Employees
- 75
- Headquarters
- Watertown, United States
- IPO year
- 2022
- Market cap
- $51.1M
- Website
- https://www.acrivon.com
Loading ACRV…
Loading profile data…Frequently asked questions about ACRV
What does Acrivon Therapeutics, Inc. Common Stock (ACRV) do?
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advan...
Where does ACRV trade?
Acrivon Therapeutics, Inc. Common Stock (ACRV) trades on the NASDAQ Global Market.
What sector is ACRV in?
Acrivon Therapeutics, Inc. Common Stock (ACRV) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Acrivon Therapeutics, Inc. Common Stock?
Peter Blume-Jensen is the chief executive officer of Acrivon Therapeutics, Inc. Common Stock (ACRV).
Where is Acrivon Therapeutics, Inc. Common Stock headquartered?
Acrivon Therapeutics, Inc. Common Stock is headquartered in United States.
Does ACRV pay a dividend?
Acrivon Therapeutics, Inc. Common Stock (ACRV) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ACRV go public?
Acrivon Therapeutics, Inc. Common Stock (ACRV) completed its initial public offering in 2022.